Trial Leaders/Researchers:
Evanthia Roussos torres, M.D.
Other Trial Staff:
Cristina De Leon, Coordinator, Grace Facio, Coordinator, Margarita Carranza, D.M., Kristy Sartor Massopust, Coordinator, America Casillas-Lopez, Coordinator, America Casillas-Lopez, Coordinator, Akshara Singareeka Raghavendra, Coordinator, Sodech Kim, Coordinator, Apoorva Vishwanath, D.M., Alix Cohen, Coordinator, Brigitte Torres, Coordinator
|
|
| | Requirement |
| 1 | Individuals of all racial and ethnic groups who are 18 years or older |
| 2 | Cohort 1: Women with a high-risk of breast cancer but no evidence of disease, including: (a) Women with BRCA1 or BRCA2 germline mutations; (b) Women with a family members with breast and/or ovarian cancer; (c) Women of Ashkenazi Jewish descent; (d) Women with a diagnosis of ovarian cancer; (e) Women with high mammographic breast density (BIRAD score 4-5); (f) Women with a history of atypical ductal hyperplasia
Cohort 2: Women with stage I-III invasive ductal or lobular breast cancer, to be enrolled prior to definitive surgery for breast cancer
Cohort 3: Women with stage IV invasive ductal or lobular breast cancer, to be enrolled at any time
Cohort 4: Women with ductal or lobular carcinoma in situ, to be enrolled at the time of diagnosis and before definitive surgery
Cohort 5: Normal controls, includes healthy family members of patients, patients with benign breast disorders, patients from families carrying a known genetic mutation who themselves are found not to carry the mutation. |
| 3 | Signed an approved study-specific informed consent and HIPAA |
| 1 | Hgb <8.0 |
| 2 | Pregnancy (except for Cohort 5) |
